Conatus Pharmaceuticals (CNAT): Jumping On The Zika Train - FBR

FBR Capital analyst, Vernon Bernadino, reiterated his Outperform rating on shares of Conatus Pharmaceuticals (NASDAQ: CNAT) after research published in the journal Nature Medicine by scientists at the National Institutes of Health (NIH) and its collaborators showed that emricasan, a small molecule, pan caspase inhibitor in Phase II development for liver cirrhosis (LC) by Conatus Pharmaceuticals, is effective in reducing the ability of Zika virus (ZIKV) to kill brain cells.

The analyst has no knowledge of any further clinical activities with emricasan in ZIKV; however, the results pose an intriguing and positive development for Conatus, as interest in emricasan by the broader medical community could accelerate its path to regulatory approval.

No change to the price target of $16.

For an analyst ratings summary and ratings history on Conatus Pharmaceuticals click here. For more ratings news on Conatus Pharmaceuticals click here.

Shares of Conatus Pharmaceuticals closed at $2.00 yesterday.

You May Also Be Interested In

• JPMorgan Upgrades Roblox Corp. (RBLX) to Overweight
• Loop Capital Starts MongoDB (MDB) at Buy, '2H Ramp Ahead'
• Piper Sandler Upgrades BlackLine (BL) to Neutral